Proximal Myopathy in Interferon Based Therapy

Muhammad Hafeez

Author(s)

Muhammad Hafeez Consultant Physician and Gastroenterologist, Combined Military Hospital, Kharian Cantt, Pakistan

Abstract

Interferon based antiviral therapy is known to have many side effects, the commonest being myalgia, fever and psychiatric problems, while the rare ones include myositis and visual changes. We report a case of a patient with chronic hepatitis C who was started on pegylated interferon and ribavirin. After four months of antiviral therapy, treatment was stopped because the patient developed proximal myopathy that lead to severe functional disability. All possible causes of proximal myopathy were excluded. After three months of stopping the treatment, a gradual improvement was noted.

Publication Details

Page(s) 137-139

DOI DOI not available

Published Journal: Journal of Pioneering Medical Sciences, Volume: 5, Issue: 4, Year: 2015

Request the full text from PASTIC

Keywords

interferon therapy, Proximal Myopathy, hepatitis C

References

Davis GL,Balart LA,Schiff ER,Lindsay K,Bodenheimer HC,Perrilo RP .1989 .Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. N Engl J Med, : 321-1501.

McHutchison JG,Gordon SC,Schiff ER,Shiffman ML,Lee WM,Rustgi VK .1998 .Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med, 339 : 1485-1492.

Manns MP,McHutchison JG,Gordon SC,Rustgi VK,Shiffman M,Reindollar R .2001 .Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358 : 958-965.

Fried MW,Shiffman ML,Reddy KR,Smith C,Marinos G,Gonçales FL .2002 .Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347 : 975-982.

Cirigliano G,Della Rossa A,Tavoni A,Viacava P,Bombardieri S. .1999 .Polymyositis occurring during alphainterferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int, 19 : 65-7.

Schleinitz N,Veit V,Labarelle A,Figarella-Branger D,Harlé JR .2000 .Polymyositis: a rare complication of interferon alpha therapy]. Rev Med Interne, 21 : 113-114.

Warabi Y,Matsubara S,Mizutani T,Hayashi H .2004 .Inclusion body myositis after interferon-alpha treatment in a patient with HCV and HTLV-1 infection. Rinsho Shinkeigaku, 44 : 609-614.

Ghilardi G,Gonvers JJ,So A .1998 .Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection. Br J Rheumatol, 37 : 1349-1351.

Kennel KA,Drake MT,Hurley DL .2010 .Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc, 85 : 752.

Golstein PE1,Delforge ML,Deviere J,Marcellin P .2004 .Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C. J Viral Hepat, 11 : 183-186.

Shiba H,Takeuchi T,Isoda K,Kokunai Y,Wada Y,Makino S,Hanafusa T .2014 .Dermatomyositis as a complication of interferon‑α therapy:a case report and review of the literature. Rheumatol Int, 34 : 1319-1322.

John A,El Emadi S,Al Kaabi S,Morad N,Derbala M,Yakoub R .2007 .Polymyositis during pegylated alphainterferon ribavirin therapy for chronic hepatitis. Indian J Gastroenterol, 26 : 147-148.

Rodríguez-Torres M. .2013 .Sofosbuvir (GS-7977), a pangenotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther, 11 : 1269-1279.

Liu X,Wang Y,Zhang G,Li N,Zhu Q,Chang H .2014 .Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients. Int J Antimicrob Agents, 44 : 145-151.

Gane EJ,Stedman CA,Hyland RH,Ding X,Svarovskaia E,Symonds WT .2013 .Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med, 368 : 34-44.